Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions.

A current review of long-term anti-rejection therapy after kidney transplantation finds that mycophenolic acid plus calcineurin inhibitors remain the backbone, but their long-term graft-survival benefit is limited, and alternatives such as belatacept and mTOR inhibitors carry their own rejection trade-offs.